News
23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction
Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by American biotechnology company Regeneron Pharmaceuticals for a cool $256 million, the highest bid submitted in the once-hot startup’s bankruptcy auction.
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.
Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...
Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...
The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
To acquire Personal Genome Service, Total Health and Research Services business lines, and its Biobank and associated assets.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback